This was the stock's third consecutive day of gains.

Zoetis was granted a conditional license for its avian influenza vaccine for use in chickens. It's a step closer to fighting ...

Both of these metrics are at their most attractive levels in the company's history, making this a once-in-a-decade opportunity. Its discounted price combined with a long track record of steady growth, ...

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Department of Agriculture (USDA) has granted conditional approval for a ...

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Greenwich Academy's 2025 commencement speaker is alumna Kristin Coveny Peck, the CEO of animal health company Zoetis. Peck graduated from Greenwich Academy in 1989. She became the company's CEO in ...

Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...

Zoetis on Feb. 14 received a conditional license from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.

Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...